Skip to main content
Alexion.US
Alexion Global Site
Contact Us
Investor Relations
Careers
US
Back to Menu
Alexion Global Site
AstraZeneca
Search
Search
About Alexion
Back to Menu
About Alexion
About Us
Leadership
Alexion Charitable Foundation
Sustainability
Our Science
Back to Menu
Our Science
Research and Development
Back to Our Science
Research and Development
Our R&D Approach
Rare Disease R&D
Leadership in Complement
Our Pipeline
Our Medicines
Innovation
Back to Our Science
Innovation
Data Science and AI
Diagnostics
Genomic Medicine
All Innovation
Therapy Areas
Back to Our Science
Therapy Areas
Bone Metabolism
Endocrinology
Hematology
Nephrology
Neurology
Rare Cancers
All Therapy Areas
Our Impact in Rare
Back to Menu
Our Impact in Rare
About Rare Disease
Back to Our Impact in Rare
About Rare Disease
Living with Rare
Health Equity in Rare
Patient Stories
Conditions we Treat
Back to Our Impact in Rare
Conditions we Treat
gMG
HPP
LAL-D
NF1-PN
NMOSD
PNH
All Conditions
Supporting Patients and Caregivers
Back to Menu
Supporting Patients and Caregivers
Support Services
Clinical Trials
Managed Access
Partnering
Back to Menu
Partnering
Discovery Partnerships
Externally Sponsored Research
Grants
Business Development
Media
Back to Menu
Media
Alexion News Centre
Fact Sheets
Articles
View All Media
Press Releases
Contact Us
Investor Relations
Careers
US
Back to Menu
Alexion Global Site
AstraZeneca
Search
Home
News Centre Resources
News Centre Resources
Leaving Our Site.
You are now going to another site.
Continue
